Emergent BioSolutions (EBS) Guides FY11, FY12 Revs Below Views
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.82 -1.43%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary 2011 financial results and provided guidance for 2012.
For 2011, the Company anticipates total revenues of $270 to $275 million, versus $275.7 million expected on the Street. With respect to 2011 net income, and before taking into account all potential adjustments related to the termination by Abbott of the co-development agreement for TRU-016, the Company anticipates net income of $20 to $24 million. These potential adjustments could include, among others, an impairment to goodwill and intangible assets to be recorded in 2011.
In addition, the Company anticipates combined year end 2011 cash, cash equivalents and investments, plus accounts receivable to be approximately $200 million.
For 2012, the Company forecasts total revenue of $280 to $300 million, split between product sales of $220 to $230 million and contracts and grants revenue of $60 to $70 million. The Company also forecasts net income of $15 to $25 million. The Street is modeling FY12 revs of $309 million.
For 2011, the Company anticipates total revenues of $270 to $275 million, versus $275.7 million expected on the Street. With respect to 2011 net income, and before taking into account all potential adjustments related to the termination by Abbott of the co-development agreement for TRU-016, the Company anticipates net income of $20 to $24 million. These potential adjustments could include, among others, an impairment to goodwill and intangible assets to be recorded in 2011.
In addition, the Company anticipates combined year end 2011 cash, cash equivalents and investments, plus accounts receivable to be approximately $200 million.
For 2012, the Company forecasts total revenue of $280 to $300 million, split between product sales of $220 to $230 million and contracts and grants revenue of $60 to $70 million. The Company also forecasts net income of $15 to $25 million. The Street is modeling FY12 revs of $309 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Etsy upgraded to buy at BofA on durable growth, buyback potential
- Advance Auto Parts falls on revenue miss, weak guidance
- Evolution Petroleum closes $16M Midland Basin royalty acquisition
Create E-mail Alert Related Categories
Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
